<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00857389</url>
  </required_header>
  <id_info>
    <org_study_id>2008-0363</org_study_id>
    <secondary_id>NCI-2012-01630</secondary_id>
    <nct_id>NCT00857389</nct_id>
  </id_info>
  <brief_title>Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies</brief_title>
  <official_title>Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Any time the words &quot;you,&quot; &quot;your,&quot; &quot;I,&quot; or &quot;me&quot; appear, it is meant to apply to the potential
      participant.

      The goal of this clinical research study is to learn if thiotepa, busulfan, and clofarabine,
      when given before an allogeneic (bone marrow , blood, or cord blood cells) or haploidentical
      (bone marrow) stem cell transplantation can help to control cancers of the bone marrow and
      lymph node system. The safety of this treatment will also be studied.

      This is an investigational study. Thiotepa and clofarabine are FDA approved and commercially
      available for the treatment of leukemia. Busulfan is FDA approved and commercially available
      for use in stem cell transplantation. The combination of thiotepa, clofarabine, and busulfan
      together with a stem cell transplant is investigational.

      Up to 60 participants will take part in this study. All will be enrolled at M. D. Anderson.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Study Drugs:

      Thiotepa and busulfan are designed to bind to DNA (genetic material of cells), which may
      cause cancer cells to die. They are commonly used in stem cell transplants.

      Clofarabine is designed to interfere with the growth and development of cancer cells.

      Study Drug Administration:

      If you are found to be eligible to take part in this study, you will begin receiving the
      study drugs before you receive the stem cell transplant.

      The days before you receive your stem cells are called minus days, such as Day -2 and Day -1.
      The day you receive the stem cells is called Day 0. The days after you receive the stem cells
      are called plus days, such as Day +1 and Day +2.

      On Day -8 (8 days before you receive the stem cell transplant), you will receive thiotepa
      through a central venous catheter (CVC) over 2 hours. A CVC is a sterile, flexible tube that
      will be placed into a large vein while you are under local anesthesia. Your doctor will
      explain this procedure to you in more detail, and you will be required to sign a separate
      consent form for this procedure.

      On Day -7, you will receive busulfan through a CVC. This dose of busulfan is a low level
      &quot;test&quot; dose to check how your blood levels change over time. This information will be used to
      decide the next dose level of busulfan.

      Blood (about 1 teaspoon each time) will be drawn 6-11 times total over Days -7 and -5 for
      pharmacokinetic (PK) testing. PK testing measures the amount of busulfan in the body at
      different time points. This PK testing will be done to find the dose of busulfan needed for
      your body size on the other days that you receive busulfan. A heparin lock line will be
      placed in a vein to lower the number of needed sticks performed for draws. If you cannot have
      the blood level tests performed for any reason, you will receive the standard busulfan dose.

      On Days -6, -5, -4, and -3, you will receive clofarabine through a CVC over 1 hour.

      On Days -5, -4, and -3, you will receive busulfan through a CVC over 3 hours.

      If you will receive stem cells from a donor whose cells do not match your own cells closely,
      on Days -4 and -3 you will also receive antithymocyte globulin (ATG) by vein over 4 hours.
      This will help to reduce the risk of your body rejecting the transplant. If your transplant
      will involve haploidentical stem cells, you will not receive ATG on Days -4 and -3.

      On Days -2 and -1, you will &quot;rest,&quot; which means you will not be given any drugs, but your CVC
      will remain in place.

      If thiotepa is not available:

      If thiotepa is not available, or if you doctor thinks it is in your best interest, you will
      receive the following study drugs and total body irradiation (TBI) before you receive the
      stem cell transplant. TBI involves the delivery of high doses of radiation designed to
      destroy cancer cells and/or lower the immune system in order to lower the risk of the body
      rejecting the new stem cells.

      Between Days -16 and -7, you will receive a low-level &quot;test&quot; dose of busulfan by vein over
      about 45 minutes to 1 hour. Test doses are used to study how your body breaks down busulfan
      and decide the dose of busulfan that you will receive. You may receive the test dose before
      Day -6 as an outpatient in the clinic, or on Day -6 as an inpatient in the hospital.

      Blood (about 1 teaspoon each time) will then be drawn for PK testing up to 11 times over the
      11 hours after the busulfan test dose and on Day -4. PK testing measures the amount of study
      drug in the body at different time points. The study staff will tell you more about the PK
      testing schedule.

      A heparin lock line will be placed in your vein before the PK testing to lower the number of
      needle sticks needed for these draws. If for any reason it is not possible for the PK tests
      to be performed, you will receive the standard dose of busulfan.

      On Day -7 or Day -6, you will be admitted to the hospital and given fluids through a CVC to
      hydrate you.

      On Days -5, -4, -3, and -2, you will receive clofarabine through a CVC over 1 hour.

      On Days -4, -3, and -2, you will receive busulfan through a CVC over 3 hours.

      If you will receive stem cells from a donor whose cells do not match your own cells closely,
      on Days -3 and -2 you will also receive antithymocyte globulin (ATG) by vein over 4 hours.
      This will help to reduce the risk of your body rejecting the transplant. If your transplant
      will involve haploidentical stem cells, you will not receive ATG on Days -3 and -2.

      On Day -1, you will receive TBI one time.

      Stem Cell Transplant:

      On Day 0, you will have an allogeneic or haploidentical stem cell transplant through the CVC.
      Allogeneic stem cells come from a donor whose cells closely match your own cells.
      Haploidentical stem cells come from a donor whose cells do not match your own cells as
      closely, but they are specially processed to help prevent graft versus host disease (GVHD).

      Receiving stem cells is similar to receiving a blood transfusion. The time required to
      receive the stem cells will depend on the type of cells you are receiving. Receiving cord
      blood stem cells can take several minutes. Receiving bone marrow and blood stem cells may
      take several hours.

      You will receive G-CSF (filgrastim) (which helps to produce white blood cells) as an
      injection under the skin once a day, starting 1 week after the transplant, until your blood
      cell levels return to normal.

      You will receive drugs (mycophenolate mofetil (MMF), tacrolimus and/or methotrexate) to help
      prevent side effects, such as GVHD. You will receive methylprednisolone if you develop GVHD.

      You will stay in the hospital for about 4 weeks after the stem cell transplantation.

      If you had a haploidentical stem cell transplant, on Days 3 and 4 after your stem cell
      transplant, you will receive cyclophosphamide through a CVC over 3 hours. Mesna will be given
      by vein at the same time you are given each dose of cyclophosphamide, to help protect your
      bladder from bleeding.

      Study Visits:

      Beginning on Day -9, once a day while you are in the hospital:

        -  You will have a physical exam, including measurements of your vital signs.

        -  You will be asked if you have had any side effects.

        -  Blood (about 4 tablespoons) will be drawn to test your blood cell counts. Two (2) times
           a week, this blood will be also be used for routine tests.

      After you are out of the hospital, 2 times a month until it has been 100 days after the
      transplant:

        -  You will have a physical exam, including measurements of your vital signs and weight.

        -  You will be asked if you have had any side effects.

        -  Blood (about 4 tablespoons) will be drawn for routine tests.

      About 1, 3, 6, and 12 months after the transplant, blood (about 4 tablespoons) will be drawn
      to check the status of the disease. You will also have bone marrow aspirations to check the
      status of the disease. You will also have a physical exam.

      If the doctor thinks it is necessary, you may have extra tests and procedures.

      Length of Study:

      You will be on study for about 1 year. You will be taken off study if the disease gets worse
      or needs further treatment.

      Follow-Up:

      If you live close to M. D. Anderson, you will return to the clinical once every several
      months for a physical exam. At these visits, blood (about 3 teaspoons) will be drawn for
      routine tests.

      You and/or your local doctor will be called every several months and asked about your health
      status and if the leukemia or MDS has come back.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2, 2009</start_date>
  <completion_date type="Actual">March 9, 2019</completion_date>
  <primary_completion_date type="Actual">March 9, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Survival Rate at 100 Days Post-transplant</measure>
    <time_frame>100 days post-transplant</time_frame>
    <description>The toxicities will be monitored and scored on a daily basis following the methods of Simon R. Practical Bayesian Guideline for Phase IIB Clinical Trials. A Bayesian stopping rule will be used to stop the trial if there is a 90% chance that the true toxicity rate exceeds the target toxicity rate of 0.25.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Disease Free Survival</measure>
    <time_frame>Up to 2 years post transplant</time_frame>
    <description>Kaplan-Meier product limit method to estimate the disease free survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Rate</measure>
    <time_frame>Up to 3 years post transplant</time_frame>
    <description>Overall Survival Rate will be estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft vs Host Disease (GVHD)</measure>
    <time_frame>Up to 30 days post transplant</time_frame>
    <description>Severity of toxicities graded according to the NCI Common Toxicity Criteria Adverse Effects (CTCAE) v3.0. Standard reporting guidelines followed for adverse events. Safety data summarized by category, severity and frequency.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Engraftment</measure>
    <time_frame>up to 100 days post transplant</time_frame>
    <description>Engraftment is most commonly defined as the first of three consecutive days of achieving a sustained peripheral blood neutrophil count of &gt;500 × 10^6/L .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events</measure>
    <time_frame>up to 30 days post transplant</time_frame>
    <description>Severity of toxicities graded according to the NCI Common Toxicity Criteria Adverse Effects (CTCAE) v3.0. Standard reporting guidelines followed for adverse events. Safety data summarized by category, severity and frequency.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse Rate of Participants Treated With Thiotepa, Busulfan, and Clofarabine</measure>
    <time_frame>Up to 2 years post transplant</time_frame>
    <description>Relapse Rate will be estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Stem Cell Transplantation</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Thio-Clo-Bu with Allo SCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-transplant conditioning regimen:
Thiotepa (Thio) + Clofarabine (Clo) + Busulfan (Blu) + Allogeneic Stem Cell Transplantation (Allo SCT) + ATG + G-CSF
Post haploidentical stem cell transplant participants:
Cyclophosphamide 50 mg/kg by vein on Days + 3 and + 4. Mesna 10 mg/kg by vein just prior to the first dose of cyclophosphamide, repeated every 4 hours for a total of ten (10) doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>5 mg/kg through a central venous catheter (CVC) over 2 hours on Day -8.</description>
    <arm_group_label>Thio-Clo-Bu with Allo SCT</arm_group_label>
    <other_name>Thio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clofarabine</intervention_name>
    <description>40 mg/m^2 through a central venous catheter (CVC) over 1 hour daily on 4 consecutive days (Days -6 through -3).</description>
    <arm_group_label>Thio-Clo-Bu with Allo SCT</arm_group_label>
    <other_name>Clo</other_name>
    <other_name>Clofarex</other_name>
    <other_name>Clolar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Test dose of 0.5 mg/kg through a central venous catheter (CVC)over 30 minutes on Day -7.
High dose 5,000 µMol-min through a central venous catheter (CVC) over 3 hours on Days -5, -4, and -3.</description>
    <arm_group_label>Thio-Clo-Bu with Allo SCT</arm_group_label>
    <other_name>Busulfex</other_name>
    <other_name>Myleran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Stem Cell Transplantation</intervention_name>
    <description>Infusion of stem cells through through a central venous catheter (CVC) On Day 0.</description>
    <arm_group_label>Thio-Clo-Bu with Allo SCT</arm_group_label>
    <other_name>ASCT</other_name>
    <other_name>SCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin (ATG)</intervention_name>
    <description>1.25 mg/kg by vein on Day -4 and 1.75 mg/kg on Day -3.</description>
    <arm_group_label>Thio-Clo-Bu with Allo SCT</arm_group_label>
    <other_name>Antithymocyte globulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF (Filgrastim)</intervention_name>
    <description>5 µg/kg Injection under the skin once a day, starting 1 week after transplant, until blood cell levels return to normal.</description>
    <arm_group_label>Thio-Clo-Bu with Allo SCT</arm_group_label>
    <other_name>Neupogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily, to be changed to oral dosing when tolerated. Tacrolimus is to be tapered as indicated after transplant day 90, if no GVHD is present. Tacrolimus is adjusted trough level of 5-15 ng/mL.</description>
    <arm_group_label>Thio-Clo-Bu with Allo SCT</arm_group_label>
    <other_name>Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>5 mg/m2 by vein on Days 1, 3 and 6 and Day +11 post transplant. The Day 11 methotrexate dose may be held as indicated if mucositis is present.</description>
    <arm_group_label>Thio-Clo-Bu with Allo SCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Post haploidentical stem cell transplant participants: 50 mg/kg by vein on Days + 3 and + 4.</description>
    <arm_group_label>Thio-Clo-Bu with Allo SCT</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesna</intervention_name>
    <description>Post haploidentical stem cell transplant participants: 10 mg/kg by vein just prior to the first dose of cyclophosphamide, repeated every 4 hours for a total of ten (10) doses.</description>
    <arm_group_label>Thio-Clo-Bu with Allo SCT</arm_group_label>
    <other_name>Mesnex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosed with one of the following diseases:

          2. Acute myelogenous leukemia (AML) in induction failure, relapse, past first remission,
             or CR1 considered at risk for relapse

          3. Myelodysplastic syndromes with International Prognostic Scoring System score (IPSS
             score) &gt;/= 2 or myelodysplasia that has not responded to chemotherapy

          4. Biphenotypic leukemia

          5. Acute lymphocytic leukemia with induction failure, first complete remission with high
             risk cytogenetics (e.g. Philadelphia positive chromosome, t(4:11) Remission requiring
             more than 2 chemotherapy to achieve remission, or any stage beyond CR1

          6. Chronic Myelogenous Leukemia (CML): second chronic phase, accelerated phase or blast
             crises with less than 10% blasts in the bone marrow, or CR1 and resistance to Gleevec
             or other tyrosine kinase inhibitors

          7. Non-Hodgkin's Lymphoma - induction failures, second or third complete remission, or
             relapse (including relapse post autologous hematopoietic stem cell transplant)

          8. Hodgkin's disease - induction failure, second or later complete remission, or relapse
             (including relapse post autologous hematopoietic stem cell transplant).

          9. Chronic Lymphocytic Leukemia that has failed induction therapy or Rai Stages 2-4

         10. Related or unrelated donor which is HLA-matched or mismatched in 1 HLA A, B, C, DR, or
             DQ locus is acceptable (i.e. &gt;/= 9/10 matched related or unrelated donor, matched with
             molecular high-resolution technique per current std. for BMT program). Cord blood
             units must match patient at 4, 5, or 6/6 HLA class 1 serological &amp; II molecular
             antigens with a min. of 2 x 10e7 TNC/kg recipient weight in the pre-thawed fraction.
             For patient lacking a matched related or unrelated donor or acceptable cord blood
             unit(s), a related haploidentical donor (&lt;/= 7/8 allele matched at A, B, C, DR loci)
             may be used.

         11. Age &lt;/= 60 years.

         12. Lansky performance score &gt;/= 50% for patients &lt;/= 16 years of age, or Zubrod
             performance status score of 0-2 for patients &gt; 16 years of age.

         13. Cardiac function - left ventricular ejection fraction &gt;/= 40%.

         14. Pulmonary function - diffusion capacity of at least 50% predicted. Children unable to
             perform pulmonary function tests (e.g. less than 7 years old) pulse oximetry of &gt;/=
             92% on room air.

         15. Serum creatinine &lt; 1.6 mg/dL or creatinine clearance &gt;/= 50 ml/min.

         16. SGPT &lt;/= 200 IU/mL, serum bilirubin &lt; 1.5 x normal.

         17. Written informed consent and assent as is age appropriate.

         18. No active infection.

        Exclusion Criteria:

          1. Pregnancy in women of child bearing potential (pregnancy test performed within 2 weeks
             of study entry).

          2. HIV positive (highly immunosuppressive treatment)

          3. Active CNS leukemia

          4. Chronic or active Hepatitis B or Hepatitis C. If questions about liver health discuss
             with PI and strongly consider liver biopsy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kris M. Mahadeo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 5, 2009</study_first_submitted>
  <study_first_submitted_qc>March 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2009</study_first_posted>
  <results_first_submitted>March 13, 2020</results_first_submitted>
  <results_first_submitted_qc>March 25, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 7, 2020</results_first_posted>
  <last_update_submitted>March 25, 2020</last_update_submitted>
  <last_update_submitted_qc>March 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Blood And Marrow Transplantation</keyword>
  <keyword>Stem Cell</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Pediatrics</keyword>
  <keyword>Bone marrow</keyword>
  <keyword>Lymph node system</keyword>
  <keyword>Allogeneic Stem Cell Transplant</keyword>
  <keyword>ASCT</keyword>
  <keyword>Busulfan</keyword>
  <keyword>Busulfex</keyword>
  <keyword>Myleran</keyword>
  <keyword>Clofarabine</keyword>
  <keyword>Clofarex</keyword>
  <keyword>Clolar</keyword>
  <keyword>Thiotepa</keyword>
  <keyword>Antithymocyte globulin</keyword>
  <keyword>ATG</keyword>
  <keyword>Thymoglobulin</keyword>
  <keyword>G-CSF</keyword>
  <keyword>Filgrastim</keyword>
  <keyword>Neupogen</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Cytoxan</keyword>
  <keyword>Neosar</keyword>
  <keyword>Mesna</keyword>
  <keyword>Mesnex</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>Prograf</keyword>
  <keyword>Methotrexate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Clofarabine</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 11, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT00857389/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study received IRB approval October 1, 2008 and was opened to recruitment March 2, 2009. The study remained open to recruitment until August 4, 2015. The study was terminated by the local IRB on April 09, 2019.</recruitment_details>
      <pre_assignment_details>Of the 60 participants enrolled, 2 participants did not proceed to transplant no data were collected for those two participants</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Conditioning Reg- Thiotepa, Busulfan, and Clofarabine</title>
          <description>Single arm study</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not proceed to transplant</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Two participants did not proceed to transplant no data were collected for those two participants</population>
      <group_list>
        <group group_id="B1">
          <title>Conditioning Reg- Thiotepa, Busulfan, and Clofarabine</title>
          <description>The 5 mg/kg over 1 hr. Busulfan was administered x 3 days over 3 hr to a daily AUC of 5,000 mcMol-min +/-10%. Clofarabine 40mg/m2 was infused over 1 hr daily x 4 days</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="58"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Survival Rate at 100 Days Post-transplant</title>
        <description>The toxicities will be monitored and scored on a daily basis following the methods of Simon R. Practical Bayesian Guideline for Phase IIB Clinical Trials. A Bayesian stopping rule will be used to stop the trial if there is a 90% chance that the true toxicity rate exceeds the target toxicity rate of 0.25.</description>
        <time_frame>100 days post-transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conditioning Reg- Thiotepa, Busulfan, and Clofarabine</title>
            <description>The 5 mg/kg over 1 hr. Busulfan was administered x 3 days over 3 hr to a daily AUC of 5,000 mcMol-min +/-10%. Clofarabine 40mg/m2 was infused over 1 hr daily x 4 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Survival Rate at 100 Days Post-transplant</title>
          <description>The toxicities will be monitored and scored on a daily basis following the methods of Simon R. Practical Bayesian Guideline for Phase IIB Clinical Trials. A Bayesian stopping rule will be used to stop the trial if there is a 90% chance that the true toxicity rate exceeds the target toxicity rate of 0.25.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Disease Free Survival</title>
        <description>Kaplan-Meier product limit method to estimate the disease free survival.</description>
        <time_frame>Up to 2 years post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conditioning Reg- Thiotepa, Busulfan, and Clofarabine</title>
            <description>The 5 mg/kg over 1 hr. Busulfan was administered x 3 days over 3 hr to a daily AUC of 5,000 mcMol-min +/-10%. Clofarabine 40mg/m2 was infused over 1 hr daily x 4 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Disease Free Survival</title>
          <description>Kaplan-Meier product limit method to estimate the disease free survival.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival Rate</title>
        <description>Overall Survival Rate will be estimated using the Kaplan-Meier method.</description>
        <time_frame>Up to 3 years post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conditioning Reg- Thiotepa, Busulfan, and Clofarabine</title>
            <description>The 5 mg/kg over 1 hr. Busulfan was administered x 3 days over 3 hr to a daily AUC of 5,000 mcMol-min +/-10%. Clofarabine 40mg/m2 was infused over 1 hr daily x 4 days</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival Rate</title>
          <description>Overall Survival Rate will be estimated using the Kaplan-Meier method.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="320" lower_limit="120" upper_limit="833"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Graft vs Host Disease (GVHD)</title>
        <description>Severity of toxicities graded according to the NCI Common Toxicity Criteria Adverse Effects (CTCAE) v3.0. Standard reporting guidelines followed for adverse events. Safety data summarized by category, severity and frequency.</description>
        <time_frame>Up to 30 days post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conditioning Reg- Thiotepa, Busulfan, and Clofarabine</title>
            <description>The 5 mg/kg over 1 hr. Busulfan was administered x 3 days over 3 hr to a daily AUC of 5,000 mcMol-min +/-10%. Clofarabine 40mg/m2 was infused over 1 hr daily x 4 days</description>
          </group>
        </group_list>
        <measure>
          <title>Graft vs Host Disease (GVHD)</title>
          <description>Severity of toxicities graded according to the NCI Common Toxicity Criteria Adverse Effects (CTCAE) v3.0. Standard reporting guidelines followed for adverse events. Safety data summarized by category, severity and frequency.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Engraftment</title>
        <description>Engraftment is most commonly defined as the first of three consecutive days of achieving a sustained peripheral blood neutrophil count of &gt;500 × 10^6/L .</description>
        <time_frame>up to 100 days post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conditioning Reg- Thiotepa, Busulfan, and Clofarabine</title>
            <description>The 5 mg/kg over 1 hr. Busulfan was administered x 3 days over 3 hr to a daily AUC of 5,000 mcMol-min +/-10%. Clofarabine 40mg/m2 was infused over 1 hr daily x 4 days</description>
          </group>
        </group_list>
        <measure>
          <title>Engraftment</title>
          <description>Engraftment is most commonly defined as the first of three consecutive days of achieving a sustained peripheral blood neutrophil count of &gt;500 × 10^6/L .</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Events</title>
        <description>Severity of toxicities graded according to the NCI Common Toxicity Criteria Adverse Effects (CTCAE) v3.0. Standard reporting guidelines followed for adverse events. Safety data summarized by category, severity and frequency.</description>
        <time_frame>up to 30 days post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conditioning Reg- Thiotepa, Busulfan, and Clofarabine</title>
            <description>The 5 mg/kg over 1 hr. Busulfan was administered x 3 days over 3 hr to a daily AUC of 5,000 mcMol-min +/-10%. Clofarabine 40mg/m2 was infused over 1 hr daily x 4 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events</title>
          <description>Severity of toxicities graded according to the NCI Common Toxicity Criteria Adverse Effects (CTCAE) v3.0. Standard reporting guidelines followed for adverse events. Safety data summarized by category, severity and frequency.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relapse Rate of Participants Treated With Thiotepa, Busulfan, and Clofarabine</title>
        <description>Relapse Rate will be estimated using the Kaplan-Meier method.</description>
        <time_frame>Up to 2 years post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Conditioning Reg- Thiotepa, Busulfan, and Clofarabine</title>
            <description>The 5 mg/kg over 1 hr. Busulfan was administered x 3 days over 3 hr to a daily AUC of 5,000 mcMol-min +/-10%. Clofarabine 40mg/m2 was infused over 1 hr daily x 4 days</description>
          </group>
        </group_list>
        <measure>
          <title>Relapse Rate of Participants Treated With Thiotepa, Busulfan, and Clofarabine</title>
          <description>Relapse Rate will be estimated using the Kaplan-Meier method.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events that were related to the preparative regimen and stem cell infusion unil 30 days post transplant.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Conditioning Reg- Thiotepa, Busulfan, and Clofarabine</title>
          <description>The 5 mg/kg over 1 hr. Busulfan was administered x 3 days over 3 hr to a daily AUC of 5,000 mcMol-min +/-10%. Clofarabine 40mg/m2 was infused over 1 hr daily x 4 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>(CTCAE) v3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Low granulocyte</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>VOD</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALK increase</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>ALT increase</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Creatinine Increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>T bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhagic Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ARDS- Acute respiratory Distress Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>DAH-diffuse alveolar hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>(CTCAE) v3.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>HSCT related microangiopathy (TA-TMA)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Secondary graft failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Dysrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred Vision</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abodominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Gastrointestinal bleeding</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Hematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Lower GI track obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Oral mucositis</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALK increased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>ALT increase</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Creatinine Increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Low platelet</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>T bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Flu like symdrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>AMS- altered mental status</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cystitis noninfective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Hemorrhagic Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Broncholitis Obliterans</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>DAH-diffuse alveolar hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Hand Foot syndrom</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>SK OTH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kris M Mahadeo, Associate Professor, Pediatrics - Patient Care</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>(713) 792-2873</phone>
      <email>kmmahadeo@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

